Stay updated on 89Zr-Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the 89Zr-Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the 89Zr-Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    A banner about NIH terminology and website-transition updates was removed. The underlying page still displays a 403 Forbidden error.
    Difference
    1%
    Check dated 2026-11-08T13:20:20.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-11-01T14:26:38.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    A site-wide notice announces an NIH content transition and says federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” under Executive Order 14434.
    Difference
    1%
    Check dated 2026-10-25T13:32:15.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T13:54:18.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The site footer now displays revision v3.7.1 instead of v3.7.0; the study page remains inaccessible with a 403 error.
    Difference
    0.2%
    Check dated 2026-10-11T14:39:07.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    Access to the study page now results in a 403 Forbidden error, replacing the previous study record content. The error page includes the 403 message and site chrome, indicating the record is currently inaccessible.
    Difference
    18%
    Check dated 2026-09-20T19:16:07.000Z thumbnail image

Stay in the know with updates to 89Zr-Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the 89Zr-Pembrolizumab in NSCLC Clinical Trial page.